Organisation
Linnane Pharma is the parent company of two public companies, which are listed on Spotlight Market.
I. Hamlet Pharma develops novel cancer therapies based on synthetic peptides and has recently reached clinical proof of concept in a controlled Phase I/II trial of bladder cancer.
Hamlet Pharma has taken the 2nd generation drug candidate Alpha1H, from discovery to clinical validation in three years. Ongoing studies include dose escalation and combination trials with established drugs. Hamlet Pharma is also extending the number of cancer indications to be tested in clinical trials.
With its unique value proposition, Hamlet Pharma has a market capitalization of approximately 800 MSEK.
II. SelectImmune Pharma develops novel alternatives to antibiotics, based on several novel drug concepts and a rich patent portfolio.
We have identified innate immunotherapy as a very promising alternative to antibiotics. Immunotherapy reduced harmful inflammation and increased bacterial elimination from infected tissues in animal models of severe infection. The effects are comparable to antibiotics but better, as it works against antibiotic resistant organisms.
SelectImmune Pharma has taken its first drug candidate from discovery to clinical validation in patients with the severe bladder pain syndrome, which is virtually untreatable. Our patented drug candidate has recently shown efficacy in a clinical study and positive effects on long-term follow-up. Further clinical trials will start shortly.
SelectImmune Pharma is listed with a current market capitalization of approximately 250 MSEK.
Linnane Pharma develops additional projects with significant potential as drugs or nutritional supplements and owns an impressive portfolio of patented new discoveries.
Development strategy
A lean and efficient process to successfully take discoveries through the required steps in a controlled drug development process into the clinic. Linnane Group has the skills and experience to bring projects from discovery through clinical trials. We will develop the projects towards Phase III trials, FDA approval and partnering for business development.
Board members, Linnane Pharma
Ines Ambite
Ines Ambite has a master’s degree in Bioengineering from the University of Toulouse, France and is a senior PhD student in Biomedicine. Her research focuses on understanding molecular mechanisms of infection and to develop novel therapeutic targets, preventive strategies and biomarkers markers of susceptibility.
Göran Streiffert
Göran Streiffert has extensive business experience, working in large corporations. Mr Streiffert was head of HR at Swedish Match and senior compliance officer at Sanitec i Helsingfors. Mr. Streiffert further adds extensive experience of research foundations and mechanisms of public support, including a role as a board member of Stiftelsen Solstickan formed by the owners of Swedish Match.
Per Olof Gunnesson, Board Member
A graduate in business administration, he has been active in the pharmaceutical industry for over fifty years, holding senior positions in finance and business development. Gunnesson worked for a long time within the Astra Group and has since been involved in smaller research companies, both in operational roles and as a board member.
Catharina Svanborg, Chairman of the board
Catharina Svanborg is the founder of Hamlet Pharma, SelectImmune Pharma and Linnane Pharma. As Professor at Lund University since 1989, she has established the strong scientific tradition and infrastructure on which the companies are built. A strong discovery and translational tradition makes it possible to take molecular discoveries through development all the way to the trials. Prof. Svanborg is a Fellow of the Royal Swedish Academy of Science since 1997, has published around 500 scientific papers, with a citation index >100 (Google scholars) and tutored about 50 graduated PhD students, many of whom hold senior positions in the scientific community. Prof. Svanborg is also the recipient of national and international awards.